• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Therapeutic advances in cardiovascular disease. >Burden of comorbidities among patients with atrial fibrillation
【24h】

Burden of comorbidities among patients with atrial fibrillation

机译：心房纤颤患者合并症的负担

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

This study examined comorbidity prevalence and general medication use among individuals with atrial fibrillation in the United States to convey a more comprehensive picture of their total disease burden. This was a retrospective, observational evaluation of responses to the 2009 wave of the annual Internet-based National Health and Wellness survey, which collects health data including epidemiologic data and information on medical treatment from a representative nationwide sample of adults in the United States. Responses were assessed to determine three measures of comorbidity: mean number of comorbidities, CHADS2 score reflecting stroke risk (0–6 points; low risk: 0; moderate risk: 1; high risk: ≥2), and scores on the Charlson Comorbidity Index, which is a measure of general comorbidity reflecting presence of a wide range of comorbidities. Of the overall sample, 1297 participants reported having been diagnosed with atrial fibrillation. Almost all (98%) of the predominantly male (65.1%) and older (≥65 years of age, 65.7%) population with atrial fibrillation had at least one additional comorbidity, and 90% had cardiovascular comorbidities. On the Charlson Comorbidity Index, 44.9% of the respondents had scores of 1–2 and 20.5% had scores of 3 or higher. High risk for stroke, demonstrated by a CHADS2 score of at least 2, was present in 45% and moderate risk (CHADS2 score 1) in 36%. Of the respondents with atrial fibrillation, 71% reported current use of medication to manage the condition, but only 48% of individuals at high risk for stroke reported use of anticoagulation therapy. Of those who reported having common risk factors for stroke, the majority reported receiving prescription therapy for these conditions. The health burden carried by patients often extends far beyond atrial fibrillation. Physicians should carefully consider comorbidities and concomitant medications when managing patients with atrial fibrillation.
机译：这项研究检查了美国房颤患者的合并症患病率和一般药物使用情况，以更全面地了解其总疾病负担。这是对基于互联网的2009年年度全国健康调查的回应的回顾性观察评估，该调查收集了来自美国全国代表性成年人样本的健康数据，包括流行病学数据和药物治疗信息。评估反应以确定三种合并症的度量：合并症的平均数，反映中风风险的CHADS2评分（0–6分;低风险：0;中度风险：1;高风险：≥2），以及查尔森合并症指数的得分，它是反映多种合并症存在的一般合并症的量度。在全部样本中，有1297名参与者报告已被诊断出房颤。几乎所有（98％）的男性房颤人群（65.1％）和年龄较大（≥65岁，65.7％）人群至少有一种合并症，而90％的患者患有心血管合并症。在查尔森合并症指数中，44.9％的受访者评分为1-2，20.5％的评分为3或更高。由CHADS2得分至少为2所证明的中风高风险发生在45％中，而中度风险（CHADS2得分为1）则为36％。在房颤患者中，有71％的人报告说目前正在使用药物治疗该病，但是只有48％的中风高危人群报告了使用抗凝治疗。在报告患有中风的常见危险因素的患者中，大多数报告了针对这些疾病的处方治疗。患者所承担的健康负担通常远远超出房颤。在处理房颤患者时，医师应仔细考虑合并症和伴随用药。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号